Members of the industry group will be able to offer up their own CBD products for safety tests, which will range from contaminant analysis to experimental rodent studies.
In an open letter to the country’s home secretary, Hannah Deacon highlights how medical cannabis remains largely unavailable to patients via the National Health Service.
Since the start of May this year, the state department has added nine pesticide products to the list, which now exceeds 400 compounds.
The registry aims to collect and analyze clinical information from patients taking medical cannabis treatments in the UK for all recognized eligible conditions.
Written by some of the country’s top drug science and policy researchers, the review puts forward a number of ‘next steps’ for the country to consider pursuing in order to better support prospective medical cannabis patients in the UK.
A partner in the testing review says the findings provide further proof that consumers should only buy from reputable CBD brands.
Researchers at George Mason University have received $450,000 in funding from the National Institutes of Health to pursue new research into whether cannabinoids can help treat HIV-associated disorders.
Compared with babies of mothers who had never used cannabis, infants of those who still consumed the drug after 15 weeks had lower mean values for birthweight, birth length, and head circumference.
The researchers aren’t sure exactly how those who used the concentrates could have such high THC levels without incurring greater intoxication, but they suspect a tolerance may have been built up.